Interstitial lung diseases von Wijsenbeek, Marlies, Suzuki, Atsushi, Maher, Toby M

Volltext

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis von Richeldi, Luca, Azuma, Arata, Cottin, Vincent, Hesslinger, Christian, Stowasser, Susanne, Valenzuela, Claudia, Wijsenbeek, Marlies S., Zoz, Donald F., Voss, Florian, Maher, Toby M.

Volltext

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat von Maher, Toby M, Strek, Mary E

Volltext

Interstitial Lung Disease: A Review von Maher, Toby M

Volltext

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK von Strongman, Helen, Kausar, Imran, Maher, Toby M.

Volltext

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development von Spagnolo, Paolo, Kropski, Jonathan A., Jones, Mark G., Lee, Joyce S., Rossi, Giulio, Karampitsakos, Theodoros, Maher, Toby M., Tzouvelekis, Argyrios, Ryerson, Christopher J.

Volltext

Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? von Byrne, Adam J, Maher, Toby M, Lloyd, Clare M

Volltext

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten von Maher, Toby M.

Volltext

Global incidence and prevalence of idiopathic pulmonary fibrosis von Maher, Toby M, Bendstrup, Elisabeth, Dron, Louis, Langley, Jonathan, Smith, Gerald, Khalid, Javaria Mona, Patel, Haridarshan, Kreuter, Michael

Volltext

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention? von Maher, Toby M

Volltext

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis von Kolb, Martin, Crestani, Bruno, Maher, Toby M

Volltext

Pulmonary fibrosis secondary to COVID-19: a call to arms? von Spagnolo, Paolo, Balestro, Elisabetta, Aliberti, Stefano, Cocconcelli, Elisabetta, Biondini, Davide, Casa, Giovanni Della, Sverzellati, Nicola, Maher, Toby M

Volltext

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases von Wollin, Lutz, Distler, Jörg H W, Redente, Elizabeth F, Riches, David W H, Stowasser, Susanne, Schlenker-Herceg, Rozsa, Maher, Toby M, Kolb, Martin

Volltext

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply von Distler, Oliver, Gahlemann, Martina, Maher, Toby M

Volltext

Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies? von Maher, Toby M

Volltext

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease von Distler, Oliver, Highland, Kristin B, Gahlemann, Martina, Azuma, Arata, Fischer, Aryeh, Mayes, Maureen D, Raghu, Ganesh, Sauter, Wiebke, Girard, Mannaig, Alves, Margarida, Clerisme-Beaty, Emmanuelle, Stowasser, Susanne, Tetzlaff, Kay, Kuwana, Masataka, Maher, Toby M

Volltext

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial von Maher, Toby M, Corte, Tamera J, Fischer, Aryeh, Kreuter, Michael, Lederer, David J, Molina-Molina, Maria, Axmann, Judit, Kirchgaessler, Klaus-Uwe, Samara, Katerina, Gilberg, Frank, Cottin, Vincent

Volltext

A clinical short‐cut to identifying short telomeres in idiopathic pulmonary fibrosis? von Maher, Toby M.

Volltext

Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply von Richeldi, Luca, Stowasser, Susanne, Maher, Toby M

Volltext

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis? von Maher, Toby M.

Volltext